Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
In the citing paper
“Capsid-specific T cell responses to AAV-based therapies were not predicted from proof-of-concept studies in animal models but were identified in human studies.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4646-4654.1996 · Cited by 609
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
Smith, T. A. G., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., McClelland, A., & Kaleko, M. (1993) · Nature Genetics · doi:10.1038/ng1293-397 · Cited by 335
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
Kay, M. A., Rothenberg, S., Landen, C. N., Bellinger, D. A., Leland, F., Toman, C., Finegold, M., Thompson, A. R., Read, M. S., Brinkhous, K. M., et al. (1993) · Science · doi:10.1126/science.8211118 · Cited by 304
Self-citation
Research works printed but not linked: 2
- Brinkhous, K.M. et al. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia. Thromb. Haemost. 69, 852 (1993 ).
- Brinkhous, K.M., Landen, C.N. & Read, M.S. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 82, suppl 1 :592a (1993).
Cited by
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAdeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
Self-citationYant, S. R., Meuse, L., Chiu, W., Ivics, Z., Izsvak, Z., & Kay, M. A. (2000) · Nature Genetics · doi:10.1038/75568 · Cited by 509
Self-citationSystemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Self-citationInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466
“IX vectors to adults with severe hemophilia B were initiated (4, 5, 8, 9).”
BackgroundViral Vectors for Gene Transfer: A Review of Their Use in the Treatment of Human Diseases
Walther, W., & Stein, U. (2000) · Drugs · doi:10.2165/00003495-200060020-00002 · Cited by 442
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Zhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330
Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice
Nakai, H., Fuess, S., Storm, T. A., Muramatsu, S.-I., Nara, Y., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.214-224.2005 · Cited by 327
Self-citationClinical gene therapy using recombinant adeno-associated virus vectors
Mueller, C., & Flotte, T. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.68 · Cited by 313
Melo, L. G., Agrawal, R., Zhang, L., Rezvani, M., Mangi, A. A., Ehsan, A., Griese, D. P., Dell’Acqua, G., Mann, M. J., Oyama, J., et al. (2002) · Circulation · doi:10.1161/hc0502.103363 · Cited by 303
Virus-mediated gene delivery for human gene therapy
Giacca, M., & Zacchigna, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.008 · Cited by 302
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
AAV vectors: is clinical success on the horizon?
Monahan, P. E., & Samulski, R. J. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301109 · Cited by 290
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
Jooss, K., & Chirmule, N. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302037 · Cited by 277
Adeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 264
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253
Self-citationEfficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6
Blankinship, M. J., Gregorevic, P., Allen, J. M., Harper, S. Q., Harper, H., Halbert, C. L., Miller, D. A., & Chamberlain, J. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.016 · Cited by 251
Flotte, T. R., Zeitlin, P. L., Reynolds, T. C., Heald, A. E., Pedersen, P., Beck, S., Conrad, C. K., Brass-Ernst, L., Humphries, M., Sullivan, K., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322124792 · Cited by 246
Miao, C. H., Ohashi, K., Patijn, G. A., Meuse, L., Ye, X., Thompson, A. R., & Kay, M. A. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0075 · Cited by 246
Self-citationDavidoff, A. M., Ng, C. Y. C., Zhou, J., Spence, Y., & Nathwani, A. C. (2003) · Blood · doi:10.1182/blood-2002-09-2889 · Cited by 244
Hemophilia therapy: the future has begun
Mannucci, P. M. (2020) · Haematologica · doi:10.3324/haematol.2019.232132 · Cited by 223
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
Wang, L., Takabe, K., Bidlingmaier, S. M., Ill, C. R., & Verma, I. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3906 · Cited by 222
Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells
Nicklin, S. A., Buening, H., Dishart, K. L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A. J., Ali, R. R., Hallek, M., & Baker, A. H. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0424 · Cited by 219
Davidoff, A. M., Gray, J. T., Ng, C. Y. C., Zhang, Y., Zhou, J., Spence, Y., Bakar, Y., & Nathwani, A. C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.022 · Cited by 218
Immune responses to adeno-associated virus and its recombinant vectors.
Sun, J. Y., Anand-Jawa, V, Chatterjee, S., & Wong, K. K. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302039 · Cited by 215
Follenzi, A., Battaglia, M., Lombardo, A., Annoni, A., Roncarolo, M. G., & Naldini, L. (2004) · Blood · doi:10.1182/blood-2003-09-3217 · Cited by 212
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy
Grimm, D., Zhou, S., Nakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Matsushita, T., Allen, J., Surosky, R., Lochrie, M., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0495 · Cited by 208
Self-citationWeber, M., Rabinowitz, J., Provost, N., Conrath, H., Folliot, S., Briot, D., Chérel, Y., Chenuaud, P., Samulski, J., Moullier, P., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00098-4 · Cited by 203
Jiang, H., Lillicrap, D., Patarroyo-White, S., Liu, T., Qian, X., Scallan, C. D., Powell, S., Keller, T., McMurray, M., Labelle, A., et al. (2006) · Blood · doi:10.1182/blood-2005-12-5115 · Cited by 200
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
Chirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P., & Wilson, J. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.5.2420-2425.2000 · Cited by 198
Nakai, H., Storm, T. A., & Kay, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9451-9463.2000 · Cited by 194
Self-citationPien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
Miao, C. H., Thompson, A. R., Loeb, K., & Ye, X. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0333 · Cited by 192
Self-citationAAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191
Recent developments in adeno‐associated virus vector technology
Büning, H., Perabo, L., Coutelle, O., Quadt‐Humme, S., & Hallek, M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1205 · Cited by 187
Herzog, R. W., Mount, J. D., Arruda, V. R., High, K. A., & Lothrop, C. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0442 · Cited by 176
Nakai, H., Storm, T. A., & Kay, M. A. (2000) · Nature Biotechnology · doi:10.1038/75390 · Cited by 176
Self-citationWang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Self-citationAdenovirus and Adeno-Associated Virus Vectors
Lai, C. M., Lai, Y. K. Y., & Rakoczy, P. E. (2002) · DNA and Cell Biology · doi:10.1089/104454902762053855 · Cited by 175
VandenDriessche, T., Vanslembrouck, V., Goovaerts, I., Zwinnen, H., Vanderhaeghen, M.-L., Collen, D., & Chuah, M. K. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10379 · Cited by 174
Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-10-3867 · Cited by 173
Self-citationXu, L., Daly, T., Gao, C., Flotte, T. R., Song, S., Byrne, B. J., Sands, M. S., & Ponder, K. P. (2001) · Human Gene Therapy · doi:10.1089/104303401300042500 · Cited by 171
CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
Arjomandnejad, M., Kopec, A. L., & Keeler, A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020287 · Cited by 171
Franco, L. M., Sun, B., Yang, X., Bird, A., Zhang, H., Schneider, A., Brown, T., Young, S. P., Clay, T. M., Amalfitano, A., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.024 · Cited by 169
Lentiviral Vectors--the Promise of Gene Therapy Within Reach?
Amado, R. G., & Chen, I. S. Y. (1999) · Science · doi:10.1126/science.285.5428.674 · Cited by 168
Large animal models and gene therapy
Casal, M. L., & Haskins, M. E. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201535 · Cited by 165
Nathwani, A. C., Davidoff, A. M., Hanawa, H., Hu, Y., Hoffer, F. A., Nikanorov, A., Slaughter, C., Ng, C. Y. C., Zhou, J., Lozier, J. N., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0589 · Cited by 164
Arruda, V. R., Schüttrumpf, J., Herzog, R. W., Nichols, T. C., Robinson, N. A., Lotfi, Y., Mingozzi, F., Xiao, W., Couto, L. B., & High, K. A. (2003) · Blood · doi:10.1182/blood-2003-05-1446 · Cited by 163
Self-citationRetinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2.
Lau, D., McGee, L. H., Zhou, S., Rendahl, K. G., Manning, W. C., Escobedo, J. A., & Flannery, J. G. (2000) · PubMed · Cited by 163
Time course of gene expression after plasmid DNA gene transfer to the liver
Herweijer, H., Zhang, G., Subbotin, V. M., Budker, V. G., Williams, P., & Wolff, J. A. (2001) · The Journal of Gene Medicine · doi:10.1002/jgm.178 · Cited by 160
Hansen, J. J., Qing, K., Kwon, H., Mah, C. S., & Srivastava, A. (2000) · Journal of Virology · doi:10.1128/jvi.74.2.992-996.2000 · Cited by 158
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
Oka, K., Pastore, L., Kim, I.-H., Merched, A. J., Nomura, S., Lee, H., Merched-Sauvage, M., Arden-Riley, C., Lee, B., Finegold, M. J., et al. (2001) · Circulation · doi:10.1161/01.cir.103.9.1274 · Cited by 153
Allay, J. A., Sleep, S., Long, S., Tillman, D. M., Clark, R., Carney, G., Fagone, P., McIntosh, J. H., Nienhuis, A. W., Davidoff, A. M., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.202 · Cited by 152
Nathwani, A. C., Davidoff, A. M., Hanawa, H., Zhou, J., Vanin, E. F., & Nienhuis, A. W. (2001) · Blood · doi:10.1182/blood.v97.5.1258 · Cited by 149
Ziegler, R. J., Lonning, S. M., Armentano, D., Li, C. Q., Souza, D. W., Cherry, M., Ford, C., Barbon, C. M., Desnick, R. J., Gao, G., et al. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.015 · Cited by 149
Herzog, R. W., Fields, P. A., Arruda, V. R., Brubaker, J. O., Armstrong, E., McClintock, D., Bellinger, D. A., Couto, L. B., Nichols, T. C., & High, K. A. (2002) · Human Gene Therapy · doi:10.1089/104303402760128513 · Cited by 147
Self-citationPermanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy
Waddington, S. N., Nivsarkar, M. S., Mistry, A., Buckley, S. M. K., Kemball‐Cook, G., Mosley, K., Mitrophanous, K., RADCLIFFE, P., Holder, M. V., Brittan, M., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0627 · Cited by 146
Efficacy of an Adeno-associated Virus 8-Pseudotyped Vector in Glycogen Storage Disease Type II
Sun, B., Zhang, H., Franco, L. M., Young, S. P., Schneider, A., Bird, A., Amalfitano, A., Chen, Y.-T., & Koeberl, D. D. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.10.004 · Cited by 145
The Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products
Mays, L. E., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.250 · Cited by 144
Miao, C. H., Nakai, H., Thompson, A. R., Storm, T. A., Chiu, W. S., Snyder, R. O., & Kay, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3793-3803.2000 · Cited by 144
Self-citationLentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes
Seppen, J., Rijnberg, M., Cooreman, M. P., & Elferink, R. P. J. O. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00308-7 · Cited by 140
Tissue-Specific Hemostasis in Mice
Mackman, N. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000183884.06371.52 · Cited by 140
Adeno-Associated Virus Gene Therapy for Liver Disease
Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138
Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer
Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., & Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0847 · Cited by 135
Home management of haemophilia
Teitel, J. M., Barnard, D., Israels, S. J., Lillicrap, D., Poon, M., & Sek, J. (2004) · Haemophilia · doi:10.1046/j.1365-2516.2003.00853.x · Cited by 132
Understanding hereditary diseases using the dog and human as companion model systems
Tsai, K. L., Clark, L. A., & Murphy, K. E. (2007) · Mammalian Genome · doi:10.1007/s00335-007-9037-1 · Cited by 131
Fields, P. A., Arruda, V. R., Armstrong, E., Chu, K., Mingozzi, F., Hagstrom, J. N., Herzog, R. W., & High, K. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0441 · Cited by 127
Favre, D., Provost, N., Blouin, V., Blancho, G., Chérel, Y., Salvetti, A., & Moullier, P. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0494 · Cited by 122
Polyelectrolyte Complexes Stabilize and Controllably Release Vascular Endothelial Growth Factor
Huang, M., Vitharana, S. N., Peek, L. J., Coop, T., & Berkland, C. J. (2007) · Biomacromolecules · doi:10.1021/bm061211k · Cited by 122
Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
LoDuca, P. A., Hoffman, B. E., & Herzog, R. W. (2009) · Current Gene Therapy · doi:10.2174/156652309787909490 · Cited by 122
Arruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P. M. B., Chen, Y.-F., Franck, H. W. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 120
Self-citationXiao, W., Chirmule, N. B., Schnell, M. A., Tazelaar, J., Hughes, J. V., & Wilson, J. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0045 · Cited by 120
Pre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes
Li, H., Murphy, S. L., Giles‐Davis, W., Edmonson, S. A., Xiang, Z., Li, Y., Lasaro, M. O., High, K. A., & Ertl, H. C. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300090 · Cited by 119
Adeno-associated virus-mediated gene delivery
Snyder, R. O. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199905/06)1:3<166::aid-jgm34>3.0.co;2-z · Cited by 118
Self-citationAdeno-Associated Viral Vectors for Gene Transfer and Gene Therapy
Büeler, H. (1999) · Biological Chemistry · doi:10.1515/bc.1999.078 · Cited by 118
Waddington, S. N., Buckley, S. M. K., Nivsarkar, M. S., Jezzard, S., Schneider, H., Dahse, T., Kemball‐Cook, G., Miah, M., Tucker, N., Dallman, M. J., et al. (2003) · Blood · doi:10.1182/blood-2002-03-0779 · Cited by 117
Sustained expression of human factor VIII in mice using a parvovirus-based vector
Chao, H., Mao, L., Bruce, A. T., & Walsh, C. (2000) · Blood · doi:10.1182/blood.v95.5.1594.005k34_1594_1599 · Cited by 116
Furler, S., Paterna, J. C., Weibel, M., & Büeler, H. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301469 · Cited by 115
Nonviral Approaches Satisfying Various Requirements for Effective in Vivo Gene Therapy.
Nishikawa, M., & Hashida, M. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.275 · Cited by 113
Mingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
Cucchiarini, M., Ren, X., Perides, G., & Terwilliger, E. F. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301925 · Cited by 111
Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P. L., Nam, H.-J., Agbandje‐McKenna, M., & Wilson, J. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803965 · Cited by 109
Lauer, P., Metzner, H. J., Zettlmeißl, G., Li, M., Smith, A. G., Lathe, R., & Dickneite, G. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613342 · Cited by 106
Persistent expression of canine factor IX in hemophilia B canines
Chao, H., Samulski, R. J., Bellinger, D. A., Monahan, P. E., Nichols, T. C., & Walsh, C. E. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301024 · Cited by 106
Self-citationXu, L., Gao, C., Sands, M. S., Cai, S., Nichols, T. C., Bellinger, D. A., Raymer, R. A., McCorquodale, S., & Ponder, K. P. (2003) · Blood · doi:10.1182/blood-2002-10-3050 · Cited by 105
Self-citationAdeno‐associated virus vectors and hematology
Russell, D. W., & Kay, M. A. (1999) · Blood · doi:10.1182/blood.v94.3.864.415k34_864_874 · Cited by 104
Self-citationBurton, M., Nakai, H., Colosi, P., Cunningham, J., Mitchell, R., & Couto, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12725 · Cited by 104
Nakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Powell, S. K., Wright, J. F., & Kay, M. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11343-11349.2002 · Cited by 104
Self-citationSystemic protein delivery by muscle-gene transfer is limited by a local immune response
Wang, L., Dobrzynski, E., Schlachterman, A., Cao, O., & Herzog, R. W. (2005) · Blood · doi:10.1182/blood-2004-03-0848 · Cited by 104
Fewell, J. G., MacLaughlin, F. C., Mehta, V. P., Gondo, M., Nicol, F., Wilson, E., & Smith, L. C. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0295 · Cited by 103
Liver gene therapy: advances and hurdles
Nguyen, T., & Ferry, N. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302373 · Cited by 102
Metadata
- Authors
- Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., Read, M. S., Bellinger, D. A., Brinkhous, K. M., & Kay, M. A.
- Affiliations
- University of Washington (US)
- Stanford Medicine (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Medicine
- Published
- 1999-01
- Volume
- 5
- Issue
- 1
- Pages
- 64-70
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- DOI
- 10.1038/4751
- OpenAlex
- W1588659566
- Cited by
- 409
- References
- 30
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 8 · 2012: 12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl001648-50)
- National Heart, Lung, and Blood Institute (HL 53682, R01HL053682, HL-01648)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, adeno-associated virus vectors, gene therapy, canine model, mouse model, liver gene transfer, coagulation correction, X-linked bleeding disorder, vector toxicity
- MeSH terms
- Dependovirus, Animals, Antibodies, Bleeding Time, Cell Transformation, Viral, Hemophilia B, Disease Models, Animal, Dogs, Factor IX, Genetic Vectors, Humans, Liver, Mice, Inbred C57BL, Recombination, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.